机构:[1]Department of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, Guangdong, China.[2]Department of Otorhinolaryngology, Longgang Otorhinolaryngology Hospital & Shenzhen Key Laboratory of Otorhinolaryngology, Shenzhen Institute of Otorhinolaryngology, No. 3004 Longgang Avenue, Shenzhen, Guangdong, China.深圳市康宁医院深圳医学信息中心[3]Department of Otorhinolaryngology, The Second People's Hospital of Yibin, Yibin, Sichuan, China
Guangdong Basic and Applied Basic Research Foundation (2021A1515010970); Shenzhen
Innovation of Science and Technology Commission (No. JCYJ20210324132407019, LGKCYLWS2022002, LGKCYLWS2021000027, LGKCYLWS2020099);
Shenzhen Key Medical Discipline Construction Fund (No. SZXK039).
语种:
外文
PubmedID:
第一作者:
第一作者机构:[1]Department of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, Guangdong, China.[2]Department of Otorhinolaryngology, Longgang Otorhinolaryngology Hospital & Shenzhen Key Laboratory of Otorhinolaryngology, Shenzhen Institute of Otorhinolaryngology, No. 3004 Longgang Avenue, Shenzhen, Guangdong, China.
通讯作者:
通讯机构:[1]Department of Graduate and Scientific Research, Zunyi Medical University Zhuhai Campus, Zhuhai, Guangdong, China.[2]Department of Otorhinolaryngology, Longgang Otorhinolaryngology Hospital & Shenzhen Key Laboratory of Otorhinolaryngology, Shenzhen Institute of Otorhinolaryngology, No. 3004 Longgang Avenue, Shenzhen, Guangdong, China.
推荐引用方式(GB/T 7714):
Ran Hong,Zhang Jin,Zeng Xiaoxia,et al.TOM40 regulates the progression of nasopharyngeal carcinoma through ROS-mediated AKT/mTOR and p53 signaling[J].Discover. Oncology.2023,14(1):109.doi:10.1007/s12672-023-00721-3.
APA:
Ran Hong,Zhang Jin,Zeng Xiaoxia,Wang Zhen,Liu Peng...&Zhang Peng.(2023).TOM40 regulates the progression of nasopharyngeal carcinoma through ROS-mediated AKT/mTOR and p53 signaling.Discover. Oncology,14,(1)
MLA:
Ran Hong,et al."TOM40 regulates the progression of nasopharyngeal carcinoma through ROS-mediated AKT/mTOR and p53 signaling".Discover. Oncology 14..1(2023):109